Playback speed
10 seconds
ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Three-Arm, Phase 2/3 GENERATE Study - NabP + Gem vs. Modified FOLFIRINOX or S-IROX in Metastatic or Recurrent Pancreatic Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
327 views
October 27, 2023
Login to view comments.
Click here to Login